H.R.830/S. 864, HELP Copays Act of 2023; Pharmacy Benefit Manager transparency, including Lower Costs, More Transparency Act, monitoring efforts around direct-to-consumer policies.
2026 · 3rd Quarter (July 1 - Sep 30)
ABBVIE, INC.
Filed by WILLIAMS AND JENSEN, PLLC.
Open official filingSource-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 20, 2026
- Income
- $90,000.00
- Expenses
- Not reported
- Registrant
- WILLIAMS AND JENSEN, PLLC
- Client
- ABBVIE, INC.
- Filing UUID
- 1a28d386-e39f-4a0f-9a32-8f914f2e0014
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Issues related to China WRT the BINSA bill.
340B Reform, FDA drug approvals, monitoring Food is Medicine initiatives, importation of biopharmaceutical products, pharmaceutical supply chain. Prescription drug advertising issues. Issues related to TrumpRX.
Drug pricing policies, implementation of IRA drug pricing policies, access and coverage, most-favored nation drug pricing policies, ORPHAN Cures Act implementation. H.R.4299 - Protecting Patient Access to Cancer and Complex Therapies Act.
Literal federal measure citations: H.R.4299
Monitoring 232 investigations, monitoring tariffs, most favored nation drug pricing policies, pharmaceutical IP issues, issues related to China WRT the BINSA bill.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.